Featured

Boehringer Ingelheim's HERNEXEOS® Approved in China for HER2-Mutant NSCLC

Boehringer Ingelheim announced the approval of HERNEXEOS® (zongertinib) by China's NMPA for treating adult patients with unresectable, locally advance...

Latest Clinical Trial Updates

October 9, 2025
Novo Nordisk to Acquire Akero Therapeutics for up to $5.2 Billion
October 7, 2025
MaxCyte and Moonlight Bio Partner to Advance T Cell Therapies for Solid Tumors
October 2, 2025
Elutia Closes BioEnvelope Business Sale to Boston Scientific for $88 Million, Focuses on NXT-41x for Breast Reconstruction Infections
September 18, 2025
Roche to Acquire 89bio for MASH Therapy Development

Empowering Life Sciences with
Advanced AI Solutions.

Book A Demo
HomeKnolsightsContact UsPricing
One Research Court, Suite 450, Rockville, MD 20850
info@pienomial.com
+91 9876543210
© 2025 Pienomial. All rights reserved
AboutTerms of ServicePrivacy Policy
Home/KnolSights/Regulatory Approvals/Boehringer Ingelheim's HERNEXEOS® Approved in China for HER2-Mutant NSCLC